Q4 2019 PCI Biotech Holding ASA Earnings Call Transcript
Good morning, everyone. And welcome to PCI Biotech fourth quarter and interim full year presentation for 2019.
My name is Per Walday. I am the CEO of PCI Biotech. I have with me also Ronny Skuggedal, who is the CFO. And in the audience we also have our most recent Board member, Hilde Furberg, present.
And we will start by just giving a background of the company and the development pipeline before going into the highlights of the fourth quarter and thereafter talk a little more into the depth of the different development programs that we have before ending it with the outlook and finances. We will open up for questions from the audience after the presentation. And we also have a webcast of this presentation, so we are also opening up for questions from the web.
So let's start. What is PCI Biotech? We are a company based on a platform technology developed by the Radium Hospital here in Oslo. It is called photochemical internalization, thereby PCI. We are focusing on oncology and we have a pipeline of 3 different programs. We call these
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
